Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-04-05
2005-04-05
Andres, Janet (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S893000, C514S894000, C514S937000, C530S300000, C530S302000
Reexamination Certificate
active
06875742
ABSTRACT:
A method of modulating cytokine mediated hepatic injury by administering compound-D SEQ ID NO:1 to a mammal. A concentration of the compound in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade. A therapeutic method of modulating cytokine mediated acute inflammatory, trauma induced and toxin induced hepatic injury, particularly via tumor necrosis factor modulation, is thus disclosed.
REFERENCES:
patent: 5656420 (1997-08-01), Chien
patent: 6103722 (2000-08-01), Schultz et al.
patent: 6380164 (2002-04-01), Oeltgen et al.
patent: WO9956766 (1999-11-01), None
Wu et al.,Delta opioid extends hypothermic preservation time of the lung, J. Thorac. Cardiovasc. Surg. 1996; 111: 259-267.
Zhao and Bhargava,Effects of multiple intracerebroventricular injections of [D-Pen2, D-Pen5] enkephalin and [D-Ala2, Glu4] deltorphin II on tolerance to their analgesic action and on brain ö-opioid receptors, Brain Research: 745 (1997) 243-247.
Barra et al.,Deltorphin, a 17 amino acid opioid peptide from the sking of the Brazilian hylid frog. Phyllomedusa burmeisteri, Peptides (Tarrytown), vol. 15, No. 2, 1994, 199-202.
Bohlinger et al.,Interleukin-1 and nitric oxide protect against tumor necrosis factor α-induced liver injury through distinct pathways, Hepatology, 22: 1829-1837, 1995.
Bolling et al.,The use of hibernation induction triggers for cardiac transplant preservation, Transplantation 63: 326-329, 1997.
Bolling et al.,Delta opioid agonist/antagonist activity and ischemic tolerance, American Heart Association Meeting, Atlanta, GA, Nov., 1999.
House et al.,A comparative study of immunomodulation produced by in vitro exposure to delta opioid receptor agonist peptides, Peptides, (1996) 17(1): 75-81.
Kevelaitis et al.,Opening of potassuim channels: The common cardioprotective link between preconditioning and natural hibernation?, Circulation 99: 3079-3085, 1999.
Leist et al.,Activation of the 55 kDA TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release, The Journal of Immunology 154: 1307-1316, 1995.
Bolling et al.,Use of “natural” hibernation induction triggers for myocardial protection, Annals Thorac. Surg.: 623-627, 1997.
Bolling et al.,Hibernation triggers and myocardial protection, Circulation 98: II-220 to II-1224, 1998.
Chien et al.,Two-day preservation of major organs with autoperfusion multiorgan preparation and hibernation induction trigger, J. Thorac. Cardiovasc. Surg., 102: 224-234, 1991.
Chien et al.,Extension of tissue survival time in multiorgan block preparation with a delta opioid DADLE ([D-Ala2, D-Leu5]-enkephalin), J. Thorac. Cardiovasc. Surg., 107: 965-967, 1994.
Crain and Shen,Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability, Pain 84 (2000), 121-131.
Fryer et al.,Opioid-induced second window of cardioprotection: Potential role of mitochondrial K-ATP channels, Circ Res. 1999; 84: 846-851.
Stefano et al.,Delta-2 opioid receptor subtype on human vascular endothelium uncouples morphine stimulated nitric oxide release, Internatonal J. Cardiology 64: Suppl. 1, S43-S51, 1998.
Thomas et al.,Structure-activity relationships of a series of 'D-Ala2-deltorphin I and II analogues: In vitro blood-brain barrier permeability and stability, Journal of Pharmacolopgy and Experiential Therapy, vol. 281, No. 2: 817-825, 1997.
Thornton, Jr. et al.,Opioid peptides and primary biliary cirrhosis, BMJ, vol. 297, No. 6662: 1501-4, 1988.
Schultz et al.,Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts, Am. J. Physiol. 268 (Heart Circ. Physiol. 3): H2157-H2161, 1995.
Schulz et al.,Involvement of activation of ATP-dependent potassium channels in ischemiec preconditioning in swine, Am. J. Physiol. 267: H1341-1352, 1994.
Schwartz et al.,Delta opioid receptors and low temperature myocardial protection, Ann. Thorac. Surg. 68: 2089-92, 1999.
Root et al., “Septicemia and septic shock”, Part Five of Infectious Diseases, Section 3, Clinical Syndromes,Harrison's Principles of Internal Medicine, 12th Ed., McGraw-Hill, 1991, 502-507.
Schultz et al.,Ischemic preconditioning in the intact rat heart is mediated by ö 1- but not μ or ×-opioid receptors, Circ 97: 1282-1289, 1998.
Schultz et al.,Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart, Circ. Research. 78: 1100-1104, 1996.
Maslov and Lishmanov,Effects of μ- and delta opioid receptor ligands on rhythm and contractility disorders of isolated rat heart in postischemic period, Kardiologya 1998; 12: 25-30 (Russian w/ English translation).
Mayfield and D'Alecy,Delta-1 opioid receptor dependence of acute hypoxic adaptation, J. Pharmacol. Exp. Ther. 268: 74-77, 1994.
Morgan,Regulation of human B lymphocyte activation by opioid peptide hormones: Inhibition of IgG production by opioid receptor class(gamma-kappa-, and delta)selective agonists, Journal of Neuroimmunology, vol. 65, No. 1: 21-30, 1996.
Oeltgen et al,The use of delta-2 opioid agonists for myocardiol ischemia protection, Abstract, Experimental Biology 2000, submitted Nov., 1999.
Oeltgen et al.,Extended lung preservation with the use of hibernation trigger factors, Ann. Thorac. Surg. 61: 1488-93, 1996.
Reisine et al.,Opioid analgesics and antagonists, Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 9th Ed., 1995, Section III Drugs Acting on the Central Nervous System, 23: 521-554.
Toombs et al.,Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide, Cardio. Res. 27: 617-622, 1993.
Tsutsui et al.,IL-18 accounts for both TNF-α- and fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice, The Journal of Immunology, 159: 3961-3967, 1997.
VanWinkle et al.,Cardioprotection provided by adenosine receptor activation is abolished by blockade of the K-ATP channel, Am. J. Physiol. 266: H829-H839, 1994.
Leist et al.,Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-αrequires transcriptional arrest, The Journal of Immunology, 153: 1778-1788, 1994.
Lishmanov et al.,Activation of the μ-opioid receptors as a factor increasing heart resistance aganist ischemic and reperfusion damages, Russian J. Physiol. 1998; 84 (11) (Russian w/ attached English translation).
Malaguarnera et al.,Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus, Journal of Gastroenterology, 32: 211-215, 1997.
Barve Shirish
Bishop Paul D.
McClain Craig J.
Oeltgen Peter R.
Andres Janet
Hamud Fozia
University of Kentucky Research Foundation
Wood Herron & Evans L.L.P.
ZymoGenetics Inc.
LandOfFree
Method for treating cytokine mediated hepatic injury does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating cytokine mediated hepatic injury, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating cytokine mediated hepatic injury will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3367990